Lu-177 DOTATATE Therapy in a Treatment Naive Metastatic NET Pineal Gland With Drop Metastasis to Spinal Cord: A Great...

Area of Science:

• Oncology
• Nuclear Medicine
• Neuro-oncology

Background:

• Neuroendocrine tumors (NETs) are typically slow-growing but can metastasize.
• Intramedullary spinal cord metastasis (ICSM) from NETs is an uncommon occurrence.
• Metastatic NETs often present with widespread disease.

Purpose of the Study:

• To report a favorable response to Peptide Receptor Radionuclide Therapy (PRRT) in a patient with metastatic neuroendocrine tumor.
• To highlight the efficacy of PRRT in a treatment-naive patient with rare spinal cord metastasis from a pineal gland NET.

Main Methods:

• The study involved a treatment-naive patient diagnosed with metastatic neuroendocrine tumor of the pineal gland.
• The patient received Peptide Receptor Radionuclide Therapy (PRRT) using Lu-177 DOTATATE.
• Tumor response was evaluated following PRRT.

Main Results:

• The patient exhibited a favorable response to Lu-177 DOTATATE PRRT.
• The treatment was effective despite the presence of brain and intramedullary spinal cord metastases.
• This indicates PRRT's potential in managing advanced NETs with rare metastatic sites.

Conclusions:

• PRRT with Lu-177 DOTATATE can be an effective treatment option for metastatic NETs, even with unusual sites like the spinal cord.
• Early PRRT may lead to favorable outcomes in treatment-naive patients with advanced metastatic NETs.
• This case underscores the importance of considering PRRT for NETs with extensive or rare metastatic involvement.